# Seer, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Seer, Inc.).

## Overview

Seer, Inc. develops the Proteograph Product Suite, a life sciences platform used to prepare and analyze proteins for deep proteomics research. The company is based in Redwood City, California and sells instruments, consumables, and related services to research and commercial customers in North America, Europe, and Asia Pacific.

## Products & services

• Proteograph Product Suite
• Proteograph consumables and assay kits
• SP200 automation instrument
• Proteomic data generation and analysis services
• Seer Technology Access Center (STAC)
• Strategic Instrument Placement Program (SIPP)

- **Instruments** (30%) — Proteograph-enabled automation and instrument systems used to run the workflow.
- **Consumables** (45%) — Assay kits, nanoparticles, reagents, and related workflow consumables.
- **Services** (20%) — Fee-for-service proteomic data generation, analysis, and access programs.
- **Other revenue** (5%) — Shipping revenue, lease arrangements, and related-party activity.

- Proteograph Product Suite
- Proteograph consumables and assay kits
- SP200 automation instrument
- Proteomic data generation and analysis services
- Seer Technology Access Center (STAC)
- Strategic Instrument Placement Program (SIPP)

## Customers

Seer sells primarily to commercial companies, academic institutions, and other research organizations that need proteomics data for discovery and translational research. Its customer base also includes related-party and strategic collaborators, and the company notes that revenue has been concentrated in a small number of customers. Customers buy the platform to access unbiased protein analysis, reduce workflow complexity, and avoid the capital burden of owning the instrument outright.

- **Commercial life sciences companies** (primary) — Buy Proteograph instruments, consumables, and services to support internal R&D and biomarker discovery.
- **Academic and research institutions** (primary) — Use the platform for population-scale and translational proteomics studies funded by grants.
- **Fee-for-service users** (secondary) — Access Proteograph workflows through STAC when they want data without owning the system.
- **Strategic and related-party accounts** (secondary) — Buy products and services through collaboration or related-party arrangements such as PrognomiQ.

- Commercial life sciences companies buying proteomics workflow access
- Academic and research institutions funding discovery studies
- Customers using STAC for fee-for-service data generation
- Users of SIPP who prefer consumables spend over upfront capex
- Related-party collaborator PrognomiQ and similar strategic accounts
- Research groups needing scalable, unbiased proteomic sample prep

## Geography

Seer is headquartered in the United States and generates most of its revenue domestically. It maintains direct sales and customer support in North America, the United Kingdom, selected EU countries, and Asia Pacific, while also using international channel partners and service centers such as STAC in Germany. Geography matters because the company’s commercial rollout depends on local scientific adoption, logistics for temperature-sensitive consumables, and access to research funding in each market.

- Headquartered in Redwood City, California
- Revenue is primarily generated in the United States
- Direct sales coverage in North America, the UK, EU, and APAC
- STAC service center opened in Bonn, Germany
- International growth depends on channel partners and local support
- Consumables logistics matter because products can be temperature controlled

## Strategy

Seer’s strategy is to broaden adoption of Proteograph by lowering access barriers and expanding the number of ways customers can use the platform. The company is building direct sales, service centers, channel partnerships, and commercial programs such as SIPP and STAC to make the workflow easier to trial, adopt, and scale. It also continues to expand manufacturing and product capabilities to support broader commercial availability and international growth.

- **Expand commercial adoption of Proteograph** (short-term) — The business depends on converting scientific interest into recurring product and service usage.
- **Lower customer adoption barriers** (short-term) — Reducing capex and workflow friction can accelerate trial and repeat usage.
- **Scale manufacturing and supply chain capacity** (medium-term) — Broader availability requires reliable production of consumables and instruments.
- **Expand international presence** (medium-term) — International markets can diversify demand and broaden the installed base.

- Reduce friction for customers to access Proteograph data
- Expand direct sales and customer experience coverage
- Use STAC to offer fee-for-service workflow access
- Use SIPP to lower upfront instrument capital barriers
- Broaden international channels and strategic partnerships
- Scale in-house nanoparticle manufacturing and product availability

## Risks

Seer is an early-stage commercial life sciences company with concentrated customers, limited operating history, and dependence on research spending. Its business also depends on successful commercialization, reliable third-party manufacturing and logistics, and continued scientific validation of the Proteograph platform. As with many analytical instrument companies, adoption risk, funding cycles, intellectual property disputes, and supply chain disruptions can materially affect results.

- **Customer concentration** [high] — A small number of customers account for a meaningful share of revenue, so lost orders can quickly reduce sales.
- **Dependence on research funding** [high] — Customers often rely on government or grant funding, so lower R&D budgets can reduce demand.
- **Commercialization execution** [high] — The company must build market acceptance for a specialized proteomics platform.
- **Supply chain and manufacturing disruption** [medium] — Instruments and consumables rely on third-party manufacturing and sourced components.
- **Intellectual property litigation** [medium] — Proteomics tools can face infringement claims that affect product availability and cost.

- Revenue concentration creates dependence on a few customers
- Demand depends on research budgets and government funding
- Commercialization may take longer than expected
- Third-party manufacturing and logistics can disrupt supply
- IP disputes could delay adoption or increase legal costs
- International expansion adds execution and channel risk

## Accounting

Seer’s accounting is driven mainly by revenue recognition across instruments, consumables, and services, including arrangements that bundle embedded software and workflow access. Investors should also watch estimates around related-party revenue, lease arrangements, and the valuation of investments and other income, because these can move reported results even when core product demand is still developing. As a commercial-stage life sciences company, it may also face judgment around inventory, warranty, and potential impairment of long-lived assets or investments.

- **Revenue recognition** — Can shift revenue between periods and between product and service lines
- **Related-party transactions** — Can affect concentration analysis and comparability
- **Lease and placement programs** — Can change revenue timing and asset classification
- **Inventory and manufacturing estimates** — Can affect gross margin and inventory carrying values
- **Fair value of investments** — Can create volatility outside core operating performance

- Revenue recognition across instruments, consumables, and services
- Bundled instrument software affects timing and allocation of revenue
- Related-party revenue can distort comparability if customer mix shifts
- Lease and SIPP arrangements may change revenue timing and balance sheet use
- Inventory and component qualification affect cost and obsolescence risk
- Investment and other income can affect non-operating results

---

*Last updated: 2026-04-29T04:57:52.666124+00:00*